

[Review Group]

## Cochrane Upper Gastrointestinal & Pancreatic Diseases Group

Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E, Bennett C, Lilleyman J, Dearness K

Contact details:

Ms Jan Lilleyman  
University of Leeds  
30-32 Hyde Terrace  
Leeds  
LS2 9LN  
UK  
enquiries@cochrane.leeds.ac.uk  
phone: +44 113 343 6778  
fax: +44 113 343 6778  
<http://cochrane.leeds.ac.uk>

*About The Cochrane Collaboration* Published in Issue 3, 2006  
Copyright © 2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

This version first published online: 15 April 2009 in Issue 2, 2009  
This record was last updated on: 25 May 2006

---

### What's new

This issue contains two new reviews and two substantively updated reviews, taking our total to 31 reviews and 26 protocols

New reviews

Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents - Alhashimi D  
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer - Yip D

Substantively updated reviews

Preoperative chemotherapy for resectable thoracic esophageal cancer - Malthaner RA  
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease - van Pinxteren B

### Editorial information

**Editorial team**

Co-ordinating Editor  
David Forman, UK

Editors

Sarah Collin, UK  
Brendan Delaney, UK  
Javier Gisbert, Spain  
Ernst Kuipers, Netherlands  
Mike Larvin, UK  
Grigoris Leontiadis, Greece  
Richard Malthaner, Canada  
Paul Moayyedi, Canada

Medical Statistician  
Sarah Collin

Review Group Co-ordinator  
Janet Lilleyman, UK

Trials Search Co-ordinator  
Iris Gordon, UK

Secretary  
Gemma Sutherland, UK

**Reviewers**

Reviewers and Co-reviewers of published protocols and reviews

This list includes only active reviewers with publications on this issue of the Cochrane Library.

A Groof  
A N Atallah  
A Roalfe  
A Rousell  
A v d Gaast  
Adam Harris  
Adrian Crellin  
Adrian Grant  
Ai Wen Wu  
Alaa Rostom  
Alan Moss  
Alex Ford  
Ali Ajaz  
Alvaro Nagib Tallah  
Alvaro Sanabria  
Amy Wen  
Ana Hanlon-Dearman  
Andrew Strickland  
Angela Wong  
Anna Dorothea Wagner  
Aravamuthan Sreedharan  
Armando Leal Mursuli  
Ashley Mowat  
Axel Grothey  
B Launois  
Bart van Pinxteren  
Brendan Delaney  
C Luo  
Carlo Fallone  
Carlos Morales-Urbe  
Catherine Dube  
Cathryn Preston  
Cathy Bennett  
Cedric Bremner  
Chittinad Havanond  
Chris Sinclair  
Christopher Steer  
Christos Karapetis  
Clare Donnellan  
Claudio Bassi  
Colin Howden  
Cristiane da Silva  
Cristina Augood  
D Girling  
D Wilke  
David Forman  
David Goldstein  
Deborah Fenlon  
Derek Alderson  
Desmond Yip  
Domenico Palli  
Duff Bruce  
E W Steyerberg  
Eduardo Villataro  
Elizabeth Elliott  
Emilie Gene  
Emilie Jolicouer  
Enrique Dominguez Munoz  
Ernst Kuipers  
Eternity Labio  
Eva Morris  
E V O'Loughlin  
F Hobbs  
F Miseiwicz

Fernando Carballo  
Francis Megraud  
Franco Bazzoli  
Francoise Themis Izquierdo Lara  
G Spiliopoulos  
Gan Tao  
George Wells  
Gerhard Kleber  
Grigoris Leontiadis  
Guajian Liu  
Guisseplina Oderda  
H Hansen  
Humberto Saconato  
Iris Gordon  
J Gama-Rodrigues  
J Brown  
J Jiafu  
J Lau  
J Q Huang  
Jon Markowitz  
James Campbell  
Jan Leyden  
Jason Goh  
Javier Gisbert  
Jayne Tierney  
Jessie McGawan  
Jiafu Wei  
Jing Xiadong  
Johannes Haerting  
John Slavin  
Jon Deeks  
Juan Antonio Castellanos Gonzalez  
K G M Parks  
K Nygaard  
Kang Yan  
Kazi Hussain  
Keith Harris  
Khurram Ayub  
Lesley Stewart  
L Hooper  
Li Yaodong  
Lin Ying  
Linda McIntyre  
Ling Tian  
Liu Ning  
Liz Gardener  
Lori Fischbach  
Lourdes Daez  
Luo Chuanxin  
M Boucher  
M Finch-Jones  
M Gignoux  
M Innes  
M Lewis  
M Parmer  
M Wang  
M W Buchler  
M Ying  
Marcelo Nita  
Maria Isabel Villegas  
Marion Campbell  
Marjolein Homs  
Mattjis Numans  
Michael Moffatt  
Mike Larvin  
Mingying Ying

Mohammed Al-Omran  
Moritz Wente  
Naoki Chiba  
Nathalie Broutet  
Ning Liu  
P A Bonis  
Padriac MacMathuna  
Pan Tao  
Paul Moayeddi  
Pengcheng Zhao  
Peter Harper  
Peter McCulloch  
Peter Siersema  
Peter Tugwell  
Peter Unge  
Piya Havanond  
Qin Wang  
Qiong Wang  
R Oakes  
Radames Isaac Adefna Perez  
Rebecca Fitzgerald  
Rebecca Wong  
Regina Imada  
Renata Kukuruzovic  
Richard Hunt  
Rick Malthaner  
Robert Laheij  
Romeu Nakamura  
Ruth Gilbert  
S Arnott  
S Wilson  
Saeed Chaudhary  
Sally Wortley  
Sam Khorrami  
Sam Wileman  
Sharon McLeer  
Shayne Taback  
Shelly Soo  
Shuli Yin  
Simon Everett  
Steven Heys  
Stuart Logan  
Suhain Alam  
Susanne Behl  
Suzanna MacLennan  
T Brown  
T Jingling  
Tian Ling  
Tom DeMeester  
Vincenzo Savarino  
Virender Sharma  
Vivian Welch  
W Duncan  
W Hongyuan  
William Craig  
Winfried Grothe  
Wolfgang Fleig  
Wui Taixiang  
X Guangwei  
X Xue  
Xavier Calvet  
Xiaoyan Yang  
Xue Xinsheng  
Yan Kang  
Ying Mingying  
Yiping Wang

Z Rhugang  
Zhen Guo  
Zhiyu Chen  
Zhonghui Wen  
Zygmunt Krukowski

**Additional contributors**

Peer referees of published protocols and reviews

We would like to thank those named below for acting as peer referees to the reviews and protocols published in the UGPD Group's module on the Cochrane Library. We are extremely grateful for your time, knowledge and help.

Ad Masclee  
Alan Barkun  
Andre Smout  
Andrew Goddard  
Angel Lanas  
Anne Duggan  
Annemiek Cats  
Brendan Drumm  
B Gold  
B. K. Sandhu  
Billy Bourke  
Brendan Delaney  
C Karalambos Gogos  
Carlo Fallone  
Carmelo Lafuente  
Casper van Eyck  
Chandu Bardhan  
Chris Dervenis  
Chris Hawkey  
Chris Williams  
Christian Gouillat  
Christoph Seiler  
Clodna McNulty  
Colm O'Morain  
Darell Heiselman  
David Armstrong  
David Cunningham  
David Kirby  
Declan Carey  
Derek Alderson  
Domenico Palli  
Dr Charnley  
Duncan Colin-Jones  
Edzard Ernst  
Eliza Wong  
Enrique Dominguez-Munoz  
Enrique Quintero  
Erik De Koster  
Erik Rauws  
Ernst Kuipers  
Fabio Luison  
Fast Feu  
Fernando Carballo  
Gretchen Purcell  
Glyn Jamieson  
Greg Rubin  
H. G. Beger  
Henk Festen  
Hugo Hazenberg  
Iain Martin  
J Dalby-Payne  
Jon Markowitz  
J Misiewicz  
J. Enrique Dominguez-Munoz  
J. N. Primrose

Jack Miller  
James Gildersleve  
Jan Dees  
Jan Hatleback  
Jan Tack  
Janusz Janowski  
Javier Gisbert  
Jayne Tierney  
Jeffrey Jackson  
Joe Sung  
Joel Richter  
John Baxter  
John De Caestecker  
John Fielding  
John Lee  
John Neoptolemus  
John Puntis  
John Toouli  
Jon Deeks  
Jorg Melzer  
Joseph Sung  
Justin Waters  
Kelvin Pamler  
Ken McColl  
Kevin Dolan  
Klaus Linde  
Kyodi Adachi  
Liisa Jaakkimainen  
Liz Gardener  
Lori Fischbach  
M S Khuroo  
M. Sinaasappel  
M. W. Buchler  
Marc Rothenberg  
Marco Bruno  
Masaharu Tatsuta  
Mattijs Numans  
Miguel Pérez-Mateo  
Mike Griffin  
Mike Larvin  
Bob Mason  
Naoki Chiba  
Nanno H. Mulder  
Niek de Wit  
Nicholas Talley  
Phil Katz  
Paul Moayyedi  
Padi Hungin  
Peter Harper  
Peer Wille-Joergensen  
Peter Matzen  
Peter Kahrilas  
Phillipa Middleton  
Peter Siersema  
Rainer Isenmann  
R. Finley  
Richard Malthaner  
Reinhard Saller  
Rene Lambert  
Robert Laheij  
Robert Heading  
S R Orenstein  
Ruth Gilbert  
Sander Van Zanten  
Seamus O'Mahony  
Sheila Greenfield

Shelly Soo  
Simon Wessely  
Thierry Conroy  
Tom Jefferson  
Vincente Garriges  
Vincenzo Savarino  
Walter Pearson  
William Steward  
Xavier Calvet

Handsearchers  
Prof Enno Hentschel  
Dr John Midgeley

**Supporting Cochrane Centre**  
UK

### **Acknowledgements**

The UGPD group acknowledge the invaluable contribution of Cathy Bennett (former Review Group Co-ordinator), Jo Webb (former Trials Search Co-ordinator) and Elizabeth Gardener (former Statistical Editor).

We also thank Robin Waxman for her proof reading assistance, and for her unique database design skills!

Contributors to the Specialised Register

Adam Harris, UK - donation of database of trials

Richard Hunt (Dr J Huang), Canada - donation of databases of trials

Jean Paul Galmiche, France - donation of extensive reference list

We gratefully acknowledge the support of the Cochrane Cancer Network in the location of trials, peer referees and general support.

The Meta Analysis Group of the MRC Trials Office, Cambridge UK converted an individual patient data review of pre-operative radiotherapy in operable cancer of the oesophagus (on behalf of the Oesophageal Cancer Collaborative Group).

### **Consumer involvement**

Consumer representative: Mr David Kirby (Oesophageal Patients Association, UK)

Any relevant involvement by consumers (people with the relevant health care condition, their carers, policy makers, health professional, and others who may make use of the reviews prepared by the CRG) is welcomed by the UGPD Group. At present, consumers act as peer referees for protocols and reviews which have been prepared by the UGPD Group. However, we intend to expand the role of consumers, possibly to include production of patient support and information leaflets, and welcome enquiries from interested parties.

### **Involvement of other users**

### **Conflict of interest**

No conflicts of interest are known

### **Background**

Discussions concerning the formation of an Upper Gastrointestinal (GI) Cochrane Review Group (CRG) began in 1993, when a number of meetings were held to develop the work of the Cochrane Collaboration in GI disease in general. These led to the formation of the Inflammatory Bowel Disease (IBD) CRG and the Hepatobiliary CRG. It was clear that there was also a need for a CRG in upper GI disease, not least because of the enormous health service costs involved in the clinical management of dyspepsia, and the burgeoning number of clinical trials of variable quality.

Professor David Forman, now Co-ordinating Editor of the UGPD Group, has a long established research interest in the clinical impact of *Helicobacter pylori* infection. This seemed to be a subject that demanded methodologically robust review if it was to lead to meaningful and practical conclusions for doctors and their patients.

A "Dyspepsia CRG" exploratory meeting took place on 16th October 1996 in Copenhagen. All those who had contacted the Cochrane Collaboration with an interest in this area of medicine were invited. Also present were people known to have an interest in reviews of dyspepsia, representatives of the IBD and Hepatobiliary CRGs, the Cochrane Cancer Network, and the two pharmaceutical companies (Glaxo-Wellcome and Astra Hassle), who had agreed to support the event. The meeting was chaired by Andy Oxman on behalf of the Collaboration.

There was unanimous and enthusiastic support at the meeting in favour of establishing a CRG, although it was felt that the scope of the Group should also include all diseases of the oesophagus, stomach and duodenum (including malignancies). To reflect this widened scope, a provisional title of "Oesophageal, Gastric and Duodenal Diseases CRG" was adopted. It was agreed that Leeds should be the editorial base for the Group and that Professor Forman should be the prospective Co-ordinating Editor.

Work commenced on obtaining the commitment of editors, reviewers and other contributors. The name changed again in

February 1998 to Upper Gastrointestinal and Pancreatic Diseases Group (UGPD), to reflect the integration of pancreatic diseases into the scope of the Group.

Formal registration of the UGPD Group took place on 1 June 1998.

Funding to support the core activities for the Group is now in place until March 2009.

#### Cochrane UGPD Group Editors' Meetings

1. 16th November 1999, at the Osservatorio Epidemiologico Regionale, Rome.
2. 27th November 2000, UEGW Meeting, in Brussels, Belgium.
3. 21st May 2001, DDW Meeting, Atlanta, US.
4. 20th May 2002, DDW Meeting, San Francisco, US.
5. 20th May 2003, DDW Meeting, Orlando, US.
6. 16th May 2005, DDW Meeting, Chicago, US.

## Scope

"To use evidence from randomised controlled trials to answer practical questions of the prevention, treatment and rehabilitation of benign and malignant disorders of the oesophagus, stomach, duodenum and pancreas. Systematic reviews of other types of trials will be used where necessary."

No orphan review topics are covered by the UGPD Group.

There are possible areas of mutual interest with other Cochrane Gastrointestinal Groups, i.e. Hepatobiliary, Inflammatory Bowel and Colorectal Cancer CRGs. Other CRGs which share a potential common interest include those which address interventions which may have an effect on the upper gastrointestinal system (for example, NSAIDs in musculoskeletal problems). Every attempt will be made to ensure that duplication of work does not occur and that support is given to other CRGs who wish to take responsibility for review topics where there is mutual interest. In particular, we would aim to support CRGs by suggesting peer referees and by searching our specialised register for appropriate trials. All interventions (surgical, pharmacological, educational, psychological etc.) for prevention, treatment (acute and maintenance) and rehabilitation will be covered.

The CRG's policy on outcome variables is under development. Many reviews will include death, recurrence of illness, improvement of symptoms or eradication of *Helicobacter pylori* as an outcome.

## Glossary

This glossary is under development and suggestions for improvement should be sent to the review group co-ordinator.

#### Achalasia (treatment)

A condition in which the ring of muscle around the junction of the oesophagus and stomach (the gastro-oesophageal sphincter) fails to relax normally on swallowing, thus allowing food to be retained in the lower part of the oesophagus.

#### Adenoid Cystic Carcinoma of Oesophagus

A type of tumour also called cylindroma, adenoid basal cell carcinoma or x carcinoma. Occurs more often in the salivary gland, rarely in the oesophagus. Cystic structures are seen microscopically, lined by flattened cells with mucoid substance in the cystic spaces.

#### Adjuvant Chemotherapy

Use of an agent (drug) in addition to the principal drug directed against a disease (see Chemotherapy), which increases the effectiveness of such a drug.

#### Alginates

These act only as a physical barrier and have no known pharmacological action. They are polyuronic acids obtained from seaweed. They are available in combination with antacids or cimetidine. Alginates form a floating raft of high pH on the surface of the gastric contents and reduce gastric reflux into the oesophagus. They also protect oesophageal mucosa from the stomach contents e.g. acid and pepsin.

#### Antacids

Substances that neutralise gastric acid in the stomach. They are systemic when they alter the acid-base balance of the body (e.g. sodium bicarbonate) and nonsystemic when they do not (e.g. magnesium trisilicate).

#### Antacids or bicarbonate with pancreatic enzymes

Given for the same reasons as above i.e. to restore normal duodenal pH and allow enzymes to operate

#### Anticholinergic drug

A drug that inhibits transmission at synapses mediated by acetylcholine. Selective drugs can either act at nicotinic cholinoreceptors or muscarinic cholinoreceptors. The term "anticholinergic" is imprecise and the type of receptor affected should be described (e.g. antimuscarinic).

#### Anti-H pylori therapy

Use of substances that are administered to inhibit or destroy the micro-organism *Helicobacter pylori*



**Anti-oxidants**

Molecular scavengers of reactive oxygen species (OH, O<sub>2</sub><sup>-</sup>) and other oxidising compounds e.g. haem compounds with high-valence iron. Examples are vitamins C and E.

**Antrectomy**

Surgical resection of the stomach distally often combined with section of the truncal vagus nerves at the oesophageal hiatus (vagotomy).

**Aprofinin**

An inhibitor of bovine pancreatic proteinase.

**Autoimmune gastritis**

Cell damage in the GI tract caused by an attack from the host's own immune system.

**Bacterial Infections of the Oesophagus**

Usually rare compared with diseases of viral and fungal origin. Tuberculosis of the oesophagus is very rare, and scarlet fever and diphtheria are now also uncommon. Occasionally in meningococemia, there may be a fibrous stricture of the oesophagus as a sequel.

**Balloon Dilatation (Tamponade)**

Use of an inflated (in situ) balloon to control variceal bleeding or recurrent haemorrhage in the upper gastrointestinal tract.

**Barrett's Oesophagus**

Intestinal metaplasia proximal to the gastro-oesophageal junction. The lower portion of the oesophagus is lined with columnar rather than squamous epithelium.

**Benign Duodenal Tumours**

Tumours with no ability to metastasise. May be polypoid, plaque like or annular and vary greatly in size. Most are mesodermal or nonepithelial in origin. Carcinoid polyps also occur. Neurogenic tumours come from the nerve sheath (neurofibromas) or the sympathetic and chromatin systems (ganglioneuromas). Inflammatory pseudo tumours with fibrous and granulation tissue, are polypoid in nature.

**Bezoar**

A concretion (solid mass) made of hair or other material found in the stomach or intestines. In man, this refers to a hair-ball found in the stomach consisting either of hair (trichobezoar) or of vegetable or fruit fibre (phytobezoar).

**Bile Reflux**

Passage of bile salts (bile) into the stomach (e.g. after gastric surgery or due to obstruction of normal bile passage in the ducts).

**Billroth I and II**

Surgical procedures carried out to reconnect the stomach and distal parts of the intestine after gastronomy. In Billroth I, the stomach and duodenum are rejoined, whereas in Billroth II the stomach and jejunum are joined, leaving a closed duodenal stump.

**Bismuth Salts**

A class of compounds used in the treatment of diarrhoea, gastro-intestinal inflammation and peptic ulceration.

**Botulinum toxin (use of)**

A bacterial toxin used in intrasphincteric injections, to paralyse the hypertensive sphincter in the gastroesophageal tract to relieve dysphagia (difficulty in swallowing).

**Brachytherapy**

Treatment applied by means of a sealed radioactive source in direct contact with body tissues.

**Calcitonin**

A natural hormone that regulates calcium metabolism. It is a polypeptide produced by the parafollicular cells of the thyroid glands.

**Calcium channel blocker (calcium antagonists)**

A drug that prevents the passage of calcium ions through calcium channels in the cell membrane.

**Camostat (Mesilate)**

An inhibitor of pancreatic enzymes given by mouth in the treatment of pancreatitis.

**Carbenoxolone**

A drug used in the treatment of peptic ulcer. The precise mode of action is uncertain.

**Celestin Dilatation**

Dilatation of oesophageal strictures using a guide wire upon which is threaded a dilator consisting of a tube with several "steps" of increasing external diameter.

#### Celiac Plexus Block

Ablation of the celiac plexus during pancreatic duodenectomy or palliative surgery by neurolysis or chemical splanchnicectomy to relieve abdominal pain.

#### Chemical, physical and drug-induced oesophagitis

Inflammation of the oesophagus carried by an exogenous chemical or physical insult or drugs.

#### Chemotherapy

Use of drugs to injure or destroy either invading organisms or cancers without (unacceptable) injury to the host.

#### Chemotherapy oesophagitis

As above, but caused as a secondary effect of chemotherapeutic drug administration.

#### Coeliac Disease

A syndrome associated with the malabsorption of foodstuffs and may be due to abnormal sensitivity of the intestinal mucosa to dietary gluten.

#### Congenital abnormalities of the duodenum

These include varying degrees of stenosis in the infant, ranging from complete absence of a lumen with two separated blind ends, or two separated segments connected by a fibrous cord or membrane, or merely a web or narrowed area impeding intestinal flow. In the adult, abnormal shape or rotation can adversely affect intestinal flow. Dilation is also encountered (mega-duodenum).

#### Congenital gastric disorders

Malfunction of the stomach linked to genetic factors.

#### Congenital oesophageal disorders

Disorders such as "rings" and "webs" (see above) emanating from congenital failure of correct oesophageal development in the embryo.

#### Coring out of Head of Pancreas

Used as a surgical procedure in the management of chronic pancreatitis. In the Beger operation the pancreatic head is first cored out and then the cored out head is drained with a Roux-en-Y (see above) limb, and the body and tail of the pancreas are drained into the jejunum with an end-to-end anastomosis.

#### Corticosteroids

A group of natural hormones (or chemical modifications of same) used in an anti-inflammatory or immune-suppressive role-as a mineralocorticoid.

#### Dumping Syndrome

There are two stages. The first stage arises by vagal stimulation caused by food dropping rapidly into the jejunum and overdistending it. A feeling of fullness, cramps, nausea, diarrhoea, palpitations, cold sweats and fainting occurs. The (rarer) late stage involves overproduction of insulin giving rise to hypoglycaemia.

#### Duodenal Carcinoma

Primary malignant cancers of the duodenum. These are rare. Typical endoscopic appearance is of an exophytic mass. Lymphoma accounts for about 20% of duodenal malignancies, mostly associated with gastric lymphoma. Most cancers arise from another primary site. Many occur as an extension into the duodenum from contiguous carcinoma of the head of the pancreas. Other cancers include primary carcinoma of the ampulla.

#### Duodenal Ischaemia

Effects caused by disorders of intestinal blood flow and diseases of vascular impairment.

#### Duodenum-preserving resection of the head of the pancreas.

Surgical procedure that spares the duodenum whilst removing the pancreatic head.

#### Eder-Puestow Dilatation

If an oesophageal stricture is too fibrous or too narrow, dilation can be performed using guided, woven dilators (bongies) passed over a string or wire. Filiform bougies (olives) are passed over the thread/wire and guided through the stricture.

#### Embolisation of Splenic Artery

Artificial blockage of the artery carried out pre-operatively in an operation for e.g. pseudocyst in chronic pancreatitis, to minimise blood loss during the operation. This could be carried out by surgical ligation.

#### Empirical Acid Suppression

Use of substances that inhibit gastric acid secretion to treat patients without knowledge of underlying pathology.

#### Empirical Anti H-pylori therapy

Use of above substances to treat patients without knowledge of underlying pathology.

#### Endoscope

An instrument comprising a flexible tube with a light source attachment, which can be passed into a patient for visual internal examination. Various therapies can be administered through the tube during internal examination whilst the area of interest is continuously monitored.

#### Endoscopic Balloon Dilation

Use of an endoscope (see above) to introduce a balloon which may be inflated to remove blockage of flow in the intestine.

#### Endoscopic dilation/drainage of bile duct

Procedure using endoscope (see above) to open up blockages of the bile duct to allow drainage of bile to occur.

#### Endoscopic Drainage

Drainage of pancreatic fluids by endoscope (see above).

#### Endoscopic Sphincterectomy

An endoscopic technique to cut the bile duct widening its diameter to allow the removal of gallstones from the bile duct.

#### Endoscopic Stenting

Use of an endoscope to place stents (see above) so as to maintain potency of ducts and thus fluid flow.

#### Endoscopic Mucosal Resection

Removal of flat gastrointestinal lesions using endoscopic techniques.

#### Enteral nutrition

Nutrition by the alimentary tract.

#### Enteric-coated preparations

Tablets etc coated with a substance resistant to gastric secretion (e.g. varnish as in enteric-coated aspirin) so that the coating is dissolved and the drug released only after they reach the small intestine.

#### Eosinophilic gastro enteritis

A disorder in which eosinophils infiltrate into the stomach, either as a localised inflammatory polyp (granuloma or hemangiopericytoma) or a diffuse modular infiltration (gastro-enteritis). Often accompanied by evidence of food allergy, but not always so.

#### Foreign Body Impaction

Objects swallowed by subjects which stick, most commonly just below the cricopharyngeus or just above the cardio-oesophageal junction, occasionally for several months. Strictures promote such capture and sticking.

#### Fundoplication

A surgical procedure often involving various degrees of wrapping the stomach around the lower end of the oesophagus, to aid in the treatment of hiatus hernia or reflux oesophagitis.

#### Fungal and Bacterial Lipase

Often contained in during preparation used to combat steatorrhea caused by pancreatic insufficiency and failure to produce endogenous lipase activity.

#### Fungal Infections of the Oesophagus organism

Can occur as monilial oesophagitis (an ulcerative pseudomembranous inflammation of the oesophagus) by *Candida albicans* or *Torulopsis glabrata*. Ordinarily found in patients whose resistance is lowered by disease or drugs e.g. those with lymphoma or leukaemia on irradiation or anti-tumour therapy, those on antibiotic or steroid therapy, some patients with diabetes mellitus or aplastic anaemia. Actinomycosis and histoplasmosis are also reported.

#### Gabexate Mesilate

A drug acting as an inhibitor of protein-degrading enzymes in pancreatitis and also used as an anticoagulant in haemodialysis.

#### Gastrectomy (total/subtotal)

Surgical excision of the stomach (in whole/ or in part.)

#### Gastric Acid Secretion Inhibitors with pancreatic enzymes.

In untreated pancreatic insufficiency there can be a significant reduction in formation of micelles of bile acids and lipid, causing lipid malabsorption. This is due to a lowered pH in the duodenum, which can be modulated to higher values by giving an inhibitor of gastric acid secretion such as cimetidine.

#### Gastric Atrophy (atrophic gastritis)

A condition where blood vessels can be seen branching through the gastric mucosa and which can exist throughout the body

and fundus of the stomach.

#### Gastric Carcinoids

Small tumours recognised as malignant though allowing long survival. They are a heterogeneous collection of growths occurring anywhere in the gut except the oesophagus. Usually well-demarcated, small, plaque-like tumours appearing yellow in cut section.

#### Gastric Erosions

Damage to the mucus lining of the stomach by acid permitting potential injury to the gastric mucosa. Can occur by drugs (e.g. aspirin) or by infection by *Helicobacter pylori*.

#### Gastric Feeding

Feeding of patient directly into the stomach by tube.

#### Gastric hamartomas

An abnormal mixture of tissue indigenous to the organ involved. In the stomach they usually come from connective tissue, showing smooth muscle, nerves and epithelial elements.

#### Gastric Ischaemia

Insufficiency of blood supply to the stomach causing pain, vomiting and distension.

#### Gastric leiomyoma and liposarcoma

A connective tissue tumour found in the stomach (see gastric polyps gastric stromal tumours).

#### Gastric polyps

Any circumscribed discrete tumour of the stomach, with varying histological characteristics (lipoma, adenoma or other small tumour).

#### Gastric Stromal Tumours

Slow-growing tumours found deep in the stroma and submucosa of the stomach. Small tumours are asymptomatic but larger ones may ulcerate and bleed. Malignant tumours are those with local invasion or distant metastasis. Previously known as smooth muscle tumours (histologically spindle cell tumours of mesenchymal origin).

#### Gastric Surgery for Obesity

Surgery involving reduction of the effective stomach volume available to food (e.g. gastric stapling).

#### Gastroenterostomy

A surgically created anastomosis (an opening between, or joining of, two or more channels, vessels, organs or spaces) between the stomach and small intestine.

#### Glucagon

A natural hormone that is an antagonist to insulin.

#### H pylori gastritis

Gastric inflammation caused by infection of the stomach by *Helicobacter pylori*.

#### Heparin

A naturally occurring substance (sulphated complex polysaccharide) especially in the liver, lung and in most cells. Used as an anti-coagulant by injection.

#### Hiatus hernia

An abnormal protrusion of part of the stomach through the oesophageal hiatus of the diaphragm into the thorax. Often associated with reflux of acid gastric contents into the lower part of the oesophagus.

#### Histamine H<sub>2</sub>-receptor therapy

Use of such substances to control gastric acid secretion.

#### Histamine H<sub>2</sub>-receptor antagonists (H<sub>2</sub>RA)

Substances that antagonise (inhibit) the promotion by histamine of increased heart rate and contractility and gastric acid secretion.

#### Intestinal metaplasia

Replacement of cells normal to the gastric epithelium with cells identical to those of the normal small intestine. A disorder causing gastritis, increasing in frequency with age and with increased levels of gastric atrophy (see).

#### Intra-operative and post-operative radiotherapy

Attempts to locally control unresectable pancreatic tumours by use of radiotherapy using electron beam therapy during operation (intraoperative) or after (post-operative). Radiation during surgery permits higher doses to be delivered to the tumour, sparing other neighbouring structures such as kidney and duodenum. External radiotherapy is more likely to damage

such structures unnecessarily.

#### Isovolaemic haemodilution

Intravenous replacement of fluid to retain adequate intravascular volume. Albumin may be also needed to sustain optimum viscosity and blood physical properties to maintain fluidity of red blood cells in the pancreatic circulation.

#### Lactose intolerance

The inability by some subjects to utilise the natural milk sugar lactose owing to the lack of the enzyme lactase.

#### Laparoscopy (peritoneoscopy)

Involves inflating the abdomen with carbon dioxide and passing a rigid peritoneoscope (apparatus for direct visualisation) into the peritoneal cavity through a small sub-umbilical incision.

#### Laser therapy

Use of an endoscope (see above) to introduce a laser beam directed at a target in the GI tract to destroy unwanted tissues.

#### Lexipafant

An antagonist of platelet-activating factor in the treatment of acute pancreatitis.

#### Lithotripsy

A technique for the destruction of gallstones in situ (extracorporeal shock wave therapy ESWL)

#### Longitudinal Pancreatico-jejunostomy

Surgery on the jejunum adjacent to the pancreas lengthways to open up the pancreatic duct after obstruction.

#### Lymphocyte gastro enteritis

Invasion of lymphocytes into the gastrointestinal tract under the influence of unknown primary inciting factors, and the resulting cytotoxicity causing injury to cells in the GI tract.

#### Maldigestion over to pancreatic disorders

This is usually due to a lack of the appropriate pancreatic secretions that contain important enzymes such as amylase for digestion of food.

#### Mallory-Weiss Tear

A mucosal tear at the oesophago-gastric junction due to forceful vomiting causing bleeding.

#### Ménétrièr Disease

A giant growth in size of the mucosal folds of the gastric mucosa associated with protein loss from the stomach and thus hypoproteinaemia.

#### Micronutrient Supplementation Treatment

Addition to the diet of vitamins, trace elements and other minerals to alloy nutritant deficiency.

#### Multimodality Therapy

Use of a multi modal approach to patients with pancreatic cancer. Choice of procedures are related to the individual needs of the patient rather than being applied indiscriminately.

#### Nasogastric Aspiration

Removal of gastric juice and air from the stomach by a nasogastric tube (see above).

#### Naso-gastric feeding

Feeding of subject by tube through the nose to the stomach.

#### Necrosectomy

Surgical removal of necrotic tissue in the pancreas during acute pancreatitis.

#### Nitrates

A class of compounds used as coronary vaso-dilators.

#### Non steroidal anti-inflammatory drugs (NSAIDS)

Drugs (not adrenocortical steroids,) that relieve inflammation, by inhibition of prostaglandin synthesis (e.g. aspirin, ibuprofen and indomethacin)

#### Non-enteric coated preparations

Tablets etc not coated to resist gastric secretions.

#### Nutrition

Administrative of suitable food or other life-sustaining material to the subject.

#### Octroetide

A drug similar to the natural hormone somatostatin. It suppresses secretion of serotonin and gastrointestinal peptides and pancreatic polypeptides. It stimulates fluid and electrolyte absorption from the gastrointestinal tract. Inhibits severe diarrhoea.

#### Oesophageal Dilatation

Opening of the oesophageal tube by physical intervention (see various dilatation techniques).

#### Oesophageal Disease caused by systemic disease

Any disorder of the oesophagus caused indirectly by other diseases with primary effects elsewhere.

#### Oesophageal Diverticulae and Pseudodiverticulae

Pharyngeal pouches present with intermittent dysphagia and regurgitation in the elderly.

#### Oesophageal intramural haematoma

Bleeding into the oesophageal wall following a) a Mallory-Weiss tear (see above), at the distal end of the oesophagus or (b) haematologic disorders or impaired haemostasis from anticoagulants (occurring anywhere in the oesophagus).

#### Oesophageal perforation

This term is reserved for perforation of the oesophagus, usually in the cervical region during endoscopy (see above). Spontaneous perforation is caused by a sudden increase in oesophageal pressure, tearing through all layers of the left lateral wall of the oesophagus just above the diaphragm (Boerhaave's syndrome).

#### Oesophageal rings

Circumferential fibrous contraction in the middle or lower third of the oesophagus (usually diagnosed radiologically) e.g. Schatzki's ring.

#### Oesophageal Small cell carcinoma

A cancer of the mucosa where the cells poorly differentiated, small, round or spindle-shaped and contain little cytoplasm. Often seen in erosive early oesophageal carcinoma.

#### Oesophageal webs

Constrictions of the oesophagus by "web like" fibrous tissue causing dysphagia. Apparently of congenital origin from misdevelopment of the embryonic oesophagus (see also oesophageal rings).

#### Oesophagogastrectomy

Resection of the oesophagus (and stomach).

#### Open Fundoplication

Performance of fundoplication (see above) by open surgery as opposed to laparoscopic (see above) methodology.

#### Opioid Analgesic

Any substance that relieves pain by effects mediated through the same class of receptors as are acted upon by morphine.

#### Palliation

Treatment undertaken with the objective of relieving symptoms, particularly when these are painful and distressing, in the knowledge that it will not affect the outcome of the disease.

#### Pancreatic duodenectomy

A surgical division of the stomach between the antrum and body followed by truncal vagotomy (see above). Used in chronic pancreatitis where the principal locus of disease is the head of the pancreas with a small pancreatic duct in the gland.

#### Pancreatic Enzymes Inhibitors

Substances used to inhibit the action of enzymes released by the pancreas that cause inflammation. These include raw soybean meal, field beans and eggs to inhibit protease, (-glucosidase inhibitors to inhibit (-amylase and tetrahydropyridin (THL) to inhibit lipase (pancreatic and gastric).

#### Pancreatic Fistula

Abnormal connections between the pancreatic duct and epithelium. They can be caused by pancreatic trauma, external drainage of pseudocysts or operation on the pancreas. Traumatic fistulas often result from pancreatic injury overlooked at initial operation.

#### Pancreatic Pseudocyst

Localised collections of pancreatic secretions that occur as a result of pancreatic inflammation. They are located in either the pancreatic parenchyma or one of the potential spaces separating the gland from the adjacent abdominal viscera.

#### Pancreatic Rests

In the stomach, the rest is usually submucosal, lying within 5 cm of the pyloric sphincter. Usually a sessile nodule 1-2 cm diameter with a centre or pit into which small ducts empty. They are benign lesions merely requiring excision.

#### Paracetamol (acetaminophen)

An important non-narcotic analgesic (pain-relieving). Less irritating to the stomach than aspirin but with no significant anti-inflammatory action.

#### Parenteral nutrition

Nutrition supplied by a route other than the alimentary tract.

#### Percutaneous Drainage

Use of aspiration via a fine needle surgically inserted through the abdomen for the drainage of e.g. pseudocysts or abscesses in the pancreas that may cause acute inflammation.

#### Percutaneous Endoscopic Gastrostomy

The placement of a tube for feeding a patient, made by penetration of the abdominal wall into the stomach, using an endoscope (see above). Often used in patients with chronic neurological disorders (e.g. stroke) who cannot swallow.

#### Peritoneal Lavage

A method of "washing out" ascitic fluid from the peritoneal cavity to remove activated pancreatic enzymes and toxins before they can be harmfully re-absorbed into the circulation. Used for acute pancreatitis.

#### Photodynamic Therapy

Intravenous administration of haematoporphyrin derivatives or dihaemato-porphyrin ether which selectively accumulates in tumour cells and, when actuated by a low-power laser results in fluorescence, cytotoxicity and tumour necrosis.

#### Platelet Aggregation Inhibitors

Substances that prevent aggregation of platelets and this tendency to form blood clots, and impedance of blood flow include aspirin, dipyridamole, sulphinpyrazone and ticlopidine hydrochloride.

#### Pre-operative Radiotherapy for Pancreatic Cancer

Use of radiotherapy to limit growth of tumours before surgical operations are undertaken.

#### Primary oesophageal lymphoma

A neoplasia primarily affecting oesophageal lymph nodes.

#### Prokinetics

Enhancement of movement, contraction or emptying, especially applied to the stomach.

#### Protease Inhibitors

Substance (see above) that inhibit the action of protease enzyme.

#### Proton-pump inhibitor

An agent that inhibits the enzyme H<sup>+</sup>/K<sup>+</sup>-adenosine triphosphatase (proton pump) of the gastric parietal cell, providing dose-related inhibition of gastric acid secretion.

#### Pseudoaneurysm

An expansion in size of the Splenic artery associated with splenic vein thrombosis and caused by the blockage of blood flow resulting from the thrombotic event.

#### Psychotropics

Drugs affecting mental function.

#### Pyloroplasty

The surgical reformation of the pylorus, the narrow muscular tube connecting the stomach to the duodenum.

#### Pylorus-preserving pancreatic duodenectomy

As for standard pancreatic duodenectomy except that the pylorus of the stomach is not removed.

#### R2 Gastrectomy

Now known as D2. Less radical than R1 (Dr), and involves the resection of nodal groups around the stomach, grouped in concentric rings, designated N1 and N2 by Japanese practice.

#### Radiation oesophagitis

As above, but caused as a secondary effect of radiation therapy.

#### Radiological Percutaneous Gastrostomy

Placement of tube for feeding a patient, made by penetration of the abdominal wall into the stomach, using radiological guidance.

#### Radiotherapy

The application of ionising radiation in the treatment of disease (almost entirely for the treatment of cancer).

#### Radiotherapy

Surgery with adjuvant chemotherapy or  
Regional Pancreatectomy

This surgical operation for pancreatic cancer involves a total pancreatectomy (see) plus removal of portions of the portal vein and in some cases, of parts of the hepatic or superior mesenteric arteries.

Resection

The removal of all or part of an organ by surgery.

RI Gastrectomy

Now known as D1. Radical but not total, gastrectomy, normally applied for removal of a gastric cancer and lymph nodes within the surrounding 5 cm. Generally performed by Western, as opposed to Japanese surgeons.

Roux-en-Y

Surgical procedure designed to reduced possibility of bile reflux.

Roux-en-Y gastrojejunostomy

A surgical technique to permit drainage of the jejunum otherwise blocked by obstruction.

Sphincterotomy

Removal of gallstones impacted in the pancreatic ducts.

Splenectomy

Surgical removal of spleen in splenic vein thrombosis, especially where there is also left-sided portal hypertension and bleeding gastric varices.

Splenic Vein Thrombosis

A vascular anomaly in the splenic vein occurring in up to 60% of patients with chronic pancreatitis undergoing surgery. Can be suspected in all patients with pseudocysts in the body or tail of the pancreas.

Stent

A device for maintaining patency of tubes in the gastrointestinal tract.

Stent

A device inserted into the pancreatic duct to relieve obstruction caused by stones. A drain is also used to remove excess fluids.

Steroid(s)

Derivative(s) of perhydrocyclo-pentanophenanthrene: a more oxygenated product of cholesterol. Many such substances are natural hormones e.g. cortisone, aldosterone, oestradiol. Included in this group are chemically modified derivatives which may also process hormonal activity and are used therapeutically.

Stromal Cell Tumour

A tumour (benign or malignant) of neuro-ectodermal origin.

Subtotal Pancreatic Resection

Partial surgical removal of some of the pancreatic gland in cases of pancreatic cancer, where total removal is not required.

Sucralfate (Cerafate, sulcrate)

The aluminium salt of a sulphurated disaccharide. It is thought to form an adherent complex with albumin and fibrinogen at the site of an ulcer, protecting it from further damage by gastric acid. It also can form a viscous adhesive barrier on the surface of the gastric mucosa and duodenum.

Surgical Biliary Drainage, Percutaneous Transhepatic Biliary Drainage

Surgical or radiological intervention to release obstruction of bile ducts by placing a tube from the bile duct to the skin.

Surgical Drainage

Direct surgical intervention to promote drainage of above.

Surgical gastrostomy

Any procedure whereby the stomach is entered by surgery.

Surgical Myotomy

Enlargement of stricture e.g. in oropharyngeal dysphasia by surgical division of musculature.

Sympathetic Blockade

Use of drugs to inhibit the sympathetic nervous system in the pancreas.

Total Pancreatectomy

Surgical removal of the entire pancreas in cases of pancreatic cancer.



**Tranexamic Acid**

A drug inhibiting the actuation of plasminogen (this decreasing the conversion of plasminogen to plasmin (the enzyme that breaks down fibrin clots.)) Used to inhibit haemorrhage.

**Tropical Sprue**

A syndrome similar to coeliac disease (see above) but occurring in tropical regions and is not caused by gluten and responds to vitamins and antibiotics.

**Tumour Resection**

Removal of tumours by surgery.

**Vagotomy**

The surgical division of one or both vagus (tenth cranial) nerves.

**Viral Infections of the Oesophagus**

In viral (herpetic) oesophagitis there is inflammation of the oesophagus associated with superficial ulceration, as a result of viral infection of the squamous cells of the oesophagus, particularly by herpes simplex virus.

**Whipple's Disease**

A chronic inflammatory disease of the bowel.

**Specialised register**

**Inclusion criteria**

The specialised register for the group will include reports of trials in any language, in the prevention, treatment and rehabilitation of benign and malignant diseases of the upper gastrointestinal tract including disorders of the oesophagus, stomach, duodenum and pancreas.

Gastrointestinal adverse effects of certain treatments, for example NSAIDs, are also included in the register of clinical trials. Oesophageal and gastric varices are included by the Hepatobiliary group, pancreatic complications of cystic fibrosis are covered by the Cystic Fibrosis Group and these are therefore not included in the UGPD register. A full list of the subjects that are covered by the group's specialised register is given in the Topics list.

**Search strategies for the identification of studies**

**Electronic searches**

The UGPD Group searches The Cochrane Controlled Trials Register to identify controlled clinical trials for inclusion in the specialised register. Handsearching of specialist journals and conference proceedings are being carried out to uncover further studies. Relevant unpublished studies will be included where available.

The UGPD Group Search Strategy for The Cochrane Controlled Trials Register has been derived from MeSH subject headings of digestive system diseases and surgical procedures, which are relevant to the scope of the Group. Appropriate free text terms have been used in conjunction with the MeSH headings to identify reports of randomised and controlled clinical trials. This strategy is under development and further search terms will be added to ensure that all trials relevant to the scope of the UGPD Group are retrieved.

In particular, further work is required to ensure that treatments and all surgical interventions for the upper gastrointestinal tract and the pancreas are adequately covered by the search terms.

The Cochrane Controlled Trials Register is searched quarterly, after each new issue of the Cochrane Library, using the following strategy.

- 1 ESOPHAGEAL-MOTILITY-DISORDERS\*:ME
- 2 GERD OR GORD
- 3(GASTRO-OESOPHAGEAL OR GASTRO-ESOPHAGEAL OR GASTROESOPHAGEAL) NEAR REFLUX
- 4 ESOPHAGITIS\*:ME
- 5 (OESOPHAGITIS or ESOPHAGITIS)
- 6 #1 OR #2 OR #3 OR #4 OR #5
- 7 ESOPHAGEAL-NEOPLASMS:ME
- 8 OESOPHAG\* OR ESOPHAG\*
- 9 NEOPLASM\* OR CANCER\* OR CARCIN\* OR MALIGNAN\* OR TUMOUR\* OR LYMPHOMA
- 10 #7 OR (#8 AND #9)
- 11 (STRICTURE OR NARROW\*)
- 12 #11 AND #8
- 13 ACHALASIA
- 14 SPHINCTER NEXT PRESSURE
- 15 #13 OR (#14 AND #8)
- 16 DYSMOTILITY OR MOTILITY
- 17 #16 AND #8
- 18 ESOPHAGEAL-DIVERTICULUM:ME
- 19 DIVERTIC\*

20 #18 OR (#19 AND #8)  
 21 RING\* AND WEB\*  
 22 (FUNGAL OR VIRAL OR BACTERIAL OR PARASITIC) AND (INFECTION OR INFECTIONS)  
 23 (#21 OR #22) AND #8  
 24 #6 OR #10 OR #12 OR #15 OR #17 OR #20 OR #23  
 25 ESOPHAGEAL-PERFORATION\*:ME  
 26 PERFORAT\* OR RUPTURE\*  
 27 MALLORY NEXT WEISS  
 28 #27 OR #25 OR (#8 AND #26)  
 29 HEMATOMA:ME  
 30 HAEMATOMA OR HEMATOMA  
 31 (#29 OR #30) AND #8  
 32 ESOPHAGEAL-ATRESIA:ME  
 33 HERNIA-HIATAL:ME  
 34 HERNIA AND HIAT\*  
 35 #32 OR #33 OR #34  
 36 ESOPHAGEAL-STENOSIS:ME  
 37 ESOPHAGEAL-FISTULA:ME  
 38 #36 OR #37  
 39 FISTUL\*  
 40 OBSTRUCTION  
 41 FOREIGN-BODIES\*:ME  
 42 #8 AND (#39 OR #40 OR #41)  
 43 #28 OR #31 OR #35 OR #38 OR #42  
 44 #24 OR #43  
 45 HELICOBACTER-PYLORI:ME  
 46 PYLORI  
 47 #45 OR #46  
 48 PEPTIC-ULCER\*:ME  
 49 STOMACH OR GASTR\* OR PEPTIC OR DUODEN\*  
 50 ULCER\*  
 51 ZOLLINGER-ELLISON  
 52 #48 OR #51 OR (#49 AND #50)  
 53 STOMACH-NEOPLASMS:ME  
 54 #53 OR (#9 AND #49)  
 55 STOMACH-DISEASES\*:ME  
 56 GASTRITIS OR MENETRIER\*  
 57 INTESTINAL AND METAPLASIA  
 58 #55 OR #56 OR #57  
 59 ATROPHY OR POLYP\*  
 60 HAMARTOMAS OR ISCHEMIA OR LIPOMA OR LIPOSARCOMA  
 61 #49 AND (#59 OR #60 OR #22)  
 62 POSTGASTRECTOMY-SYNDROMES\*:ME  
 63 DUMPING NEAR SYNDROME  
 64 #58 OR #61 OR #62 OR #63  
 65 CELIAC-DISEASE:ME  
 66 WHIPPLES-DISEASE:ME  
 67 SPRUE-TROPICAL:ME  
 68 LACTOSE-INTOLERANCE:ME  
 69 CELIAC OR WHIPPLE\* OR (TROPICAL AND SPRUE) OR (LACTOSE AND INTOLER\*)  
 70 #65 OR #66 OR #67 OR #68 OR #69  
 71 GASTROINTESTINAL-HEMORRHAGE\*:ME  
 72 HEMORRHAGE OR HAEMORRHAGE OR BLEED\* OR REBLEED\*  
 73 PERFORAT\* OR RUPTURE\*  
 74 #71 OR ((#72 OR #73) AND #49)  
 75 DUODENAL-DISEASES:ME  
 76 AFFERENT-LOOP-SYNDROME:ME  
 77 #75 OR #76  
 78 DYSPEPSIA:ME  
 79 GASTROPARESIS  
 80 REFLUX OR EROSION  
 81 #80 AND #49  
 82 #78 OR #79 OR #81  
 83 #44 OR #47 OR #52 OR #54 OR #64 OR #70 OR #74 OR #77 OR #82  
 84 ENDOSCOPY-DIGESTIVE-SYSTEM:ME  
 85 DUODENOSCOPY:ME

86 GASTROSCOPY:ME  
 87 ESOPHAGOSCOPY:ME  
 88 CHOLANGIOPANCREATOGRAPHY-ENDOSCOPIC-RETROGRADE:ME  
 89 ERCP OR (ENDOSCOPIC AND RETROGRADE AND CHOLANGIOPANCREATOGRAPHY)  
 90 ENDOSCOPI\* OR DUODENOSCOPI\* OR GASTROSCOP\*  
 91 #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #90  
 92 FUNDOPLICATION:ME  
 93 FUNDOPLICATION  
 94 #92 OR #93  
 95 DILATATION:ME  
 96 BALLOON-DILATATION\*:ME  
 97 (((EDER-PEUSTOW or CELESTIN) or BALLOON) AND DILATATION)  
 98 #8 AND (#95 OR #96 OR #97)  
 99 DUODENOSTOMY:ME  
 100 ESOPHAGECTOMY:ME  
 101 ESOPHAGOPLASTY:ME  
 102 ESOPHAGOSTOMY:ME  
 103 ESOPHAGOGASTRECTOMY OR OESOPHOGASTRECTOMY  
 104 GASTRECTOMY:ME  
 105 ENDOSCOPIC AND MUCOSAL AND RESECTION  
 106 #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105  
 107 BILROTH OR ROUX-EN-Y  
 108 ANASTOMOSIS-ROUX-EN-Y:ME  
 109 VAGOTOMY\*:ME  
 110 VAGOTOMY AND (GASTROENTEROSTOMY OR PYLOROPLASTY)  
 111 GASTROENTEROSTOMY\*:ME  
 112 #107 OR #108 OR #109 OR #110 OR #111  
 113 GASTROPLASTY:ME  
 114 GASTROSTOMY:ME  
 115 JEJUNOSTOMY:ME  
 116 GASTROJEJUNOSTOMY OR JEJUNOSTOMY  
 117 #113 OR #114 OR #115 OR #116  
 118 #106 OR #112 OR #117  
 119 #83 OR #91 OR #98 OR #118  
 120 ANTI-ULCER-AGENTS:ME  
 121 ANTIULCER NEXT AGENT\*  
 122 ANTI-ULCER NEXT AGENT\*  
 123 #120 OR #121 OR #122  
 124 HISTAMINE-H2-ANTAGONISTS:ME  
 125 HISTAMINE NEAR ANTAGONIST\*  
 126 RECEPTOR\* NEAR ANTAGONIST\*  
 127 CIMETIDINE:ME  
 128 FAMOTIDINE:ME  
 129 NIZATIDINE:ME  
 130 RANITIDINE:ME  
 131 CIMETIDINE OR FAMOTIDINE OR NIZATIDINE OR RANITIDINE  
 132 #124 OR #125 OR #126 OR #127 OR #128 OR #129 OR #130 OR #131  
 133 OMEPRAZOLE:ME  
 134 (PROTON NEXT PUMP) NEAR INHIBITOR\*  
 135 (PROTON NEXT PUMP) NEAR BLOCKER\*  
 136 OMEPRAZOLE OR LANSOPRAZOLE OR PANTOPRAZOLE OR RABEPRAZOLE  
 137 #133 OR #134 OR #135 OR #136  
 138 PROKINETIC NEAR AGENT\*  
 139 ERYTHROMYCIN OR DOMPERIDONE OR METOCLOPRAMIDE OR CISAPRIDE  
 140 ERYTHROMYCIN:ME  
 141 DOMPERIDONE:ME  
 142 METOCLOPRAMIDE:ME  
 143 #138 OR #139 OR #140 OR #141 OR #142  
 144 ALGINATES:ME  
 145 ALUMINUM-HYDROXIDE:ME  
 146 ALGICON OR ALGINATE\*  
 147 CALCIUM-CARBONATE:ME  
 148 MAGNESIUM-HYDROXIDE:ME  
 149 MAGNESIUM-OXIDE:ME  
 150 SODIUM-BICARBONATE:ME  
 151 #144 OR #145 OR #146 OR #147 OR #148 OR #149 OR #150

152 ALTACITE\* OR ASILONE\*  
153 GASTROCOTE\* OR GAVISCON\*  
154 HYDROTALCITE\* OR MAALOX\*  
155 MUCAINE  
156 #152 OR #153 OR #154 OR #155  
157 ALUMIN\* NEXT HYDROXIDE\*  
158 CALCIUM NEXT CARBONATE\*  
159 MAGNESIUM NEXT HYDROXIDE\*  
160 MAGNESIUM NEXT OXIDE\*  
161 MAGNESIUM NEXT TRISILICATE\*  
162 SODIUM NEAR BICARBONATE\*  
163 SODIUM NEAR CARBONATE\*  
164 #157 OR #158 OR #159 OR #160 OR #161 OR #162 OR #163  
165 CARBENOXOLONE:ME  
166 MISOPROSTOL:ME  
167 SUCRALFATE:ME  
168 MUCOSAL AND PROTECTING AND AGENT\*  
169 CARBENOXOLONE OR MISOPROSTOL OR SUCRALFATE  
170 #165 OR #166 OR #167 OR #168 OR #169  
171 MUSCARINIC-ANTAGONISTS:ME  
172 DICYCLOMINE:ME  
173 PIRENZEPINE:ME  
174 PROPANTHELINE:ME  
175 ANTIMUSCARINIC\*  
176 MUSCARINIC NEAR ANTAGONIST\*  
177 DICYCLOMINE OR METHANTHELINE OR PIRENZEPINE  
178 PROPANTHELINE  
179 #171 OR #172 OR #173 OR #174 OR #175 OR #176 OR #177 OR #178  
180 #123 OR #132 OR #137 OR #143 OR #151 OR #156 OR #164 OR #170 OR #179  
181 #119 or (#180 and (#49 or #8))

### **Hand searching**

The UGPD has registered with the New England Cochrane Centre their intention to handsearch the following specialist journals:

Journals:

Acta Medica Austriaca 1990-

Cancer Research, 1980-

Alimentary Pharmacology and Therapeutics, 1987-

Canadian Journal of Gastroenterology. 1987-

Digestive Endoscopy. 1989-

European Journal of Gastroenterology & Hepatology. (1989-1994)

Helicobacter. 1996-

International Journal of Pancreatology. 1986-

Pancreas. 1986-

Conference Proceeding:

Digestive Disease Week. 1997 May 11-14; Washington DC.

Journals being handsearched by the Biomed project for the UGPD Group

The Biomed handsearching project is a three year project in which seven European Cochrane Centres collaborate to handsearch western European specialized health care journals. The Biomed project has undertaken to handsearch the following journals on behalf of the UGPD group:

Acta Endoscopica.

Acta Gastro-enterologica Belgica.

Annales de Gastroenterologie et d'Hepatology.

Chirurgia Gastroenterologica.

Chirurgische Gastroenterologie

Endoskopie Heute.

Gastrum Patologia del Aparato Digestva.

Gastro-Enterologie Clinique et Biologie.

Gastro-Enterologia y Hepatologia.

Gastroenterologisches Journal.

Italian Journal of Gastroenterology and Hepatology.

Revisiones en Gastroenterologia.

Revista Andaluza de Patologia Digestiva.

Revista de la Asociacion Castellana del Aparato Digestivo.

Revista Espanola de Enfermedades Digestivas.

Revue Francaise de Gastro-enterologie.

Sociedad Valenciana de Patología Digestiva

### ***Other strategies***

For each review a search strategy is produced based on relevant clinical terms agreed by the reviewer and the Trials Search Co-ordinator. The search strategy is constructed using a combination of Mesh terms and free text terms. All reports of randomised controlled trials identified whilst searching will be added to the Group's Specialised Register. Where applicable, the following information sources are searched using an individual search strategy developed for each review:

The Cochrane Library

Medline

Embase

Cinahl

Cancerlit

Web of Science

LILACS

PDQ

PsychINFO

AHMED

Current Contents

SIGLE

The following information sources are searched for all reviews:

National Research Register

Medical Research Council (MRC)

Center Watch.

Clinicaltrials.gov

Current Controlled Trials

TrialsCentral

The UGPD Group has been fortunate to receive bibliographies from Adam Harris (UK), Richard Hunt (Canada) and Jean Paul Galmiche (France), which have been searched and the relevant trials added to our specialised register.

### ***Planned searching activities***

We have identified several non-English language journals and conference proceedings which we feel may contain reports of trials relevant to our Group. These include Japanese Journal of Gastroenterology, Gastroenterological Society of Taiwan Journal, Endoskopie Heute, and many others. However, at present we are unable to identify handsearchers for these, accordingly we have not registered them on the Cochrane Handsearching Masterlist. If you are able to help us with searching non-English language journals, please contact our Trials Search Co-ordinator.

## **Methods used in reviews**

### **Search strategies**

#### ***Access to specialised register by reviewers***

The specialised register is available for all reviewers to consult through the Cochrane Library. However, to avoid duplication of searching activities and to provide reviewers with a comprehensive search of the database, the Trials Search Co-ordinator will liaise with reviewers to construct and develop search strategies for each review, to be carried out at the editorial base.

Searches for updating reviews will be carried out at the editorial base by the Trials Search Co-ordinator on an annual basis.

#### ***Additional search strategies***

The Trials Search Co-ordinator will work with the reviewer to create a specific search strategy for each reviewer, which will then be run in EMBASE, CINAHL, and BIDS ISI, in addition to the Cochrane Library. The UGPD Group also liaises with the Cancer Network when searching for reviewers with cancer related topics. In order to identify unpublished trials, experts in the field and pharmaceutical companies will be contacted for information, and, where applicable, the Internet will also be searched. Reports of trials found by these methods will be added to the UGPD register of trials. Reviewers should search citations in each trial report for additional trials.

### **Study selection**

The UGPD Group recommends that the trials included are randomised, pseudorandomised or controlled clinical trials which compare the test intervention with placebo or standard treatment.

Other types of trials can be used where necessary

Selection of studies for inclusion in a review should be performed independently by more than one reviewer. The editorial base will assist with this if an independent reviewer cannot be found.

The editor assigned to the review will work to resolve differences in study selection between reviewers.

### **Assessment of methodological quality**

Procedures for the assessment of methodological quality are under development.

Advice on standard criteria for assessing quality will be given by the editorial team. Examples of quality assessment checklists are available. Methods are described in the Cochrane Reviewers Handbook which is available from the editorial team, on the

Cochrane library and via the Cochrane Web sites.

In general:

An accepted method of quality assessment should be used.

Quality should be independently assessed by more than one reviewer and the level of agreement should be reported in the review.

The editor responsible for the development of the review will resolve difference in quality assessment between reviewers. Quality assessment will be reported in the methods and results sections of the review.

### **Data collection**

The UGPD group recommends that the extraction of data is done independently by more than one reviewer. The editor responsible for the development of the review will resolve difference in data interpretation between reviewers. Data verification with the person responsible for the study will not normally be required other than where the data is unpublished or confirmation of results are required.

Data from RCTs that have not been published will be eligible for use in systematic reviews prepared by the UGPD group, subject to verification of data by the primary investigator. The UGPD Group will not routinely collect and analyse data on rare adverse events collected from non-RCTS.

### **Analysis**

Statistical guidance is available from the editorial base (Statistical Editor: Liz Gardener).

Data entry to RevMan should be done using the double data entry facility which allows more than one reviewer to independently enter data. Where this cannot be done (e.g. single author review) the editorial base will work with the reviewer to ensure that data entry is accurate.

Policies on statistical methods are under development.

These will incorporate guidance derived from Section 8.5 of the Reviewers Handbook on Standard statistical methods and the use of confidence intervals.

Heterogeneity of trials and issues such as crossover trials will be addressed.

### **Reporting of reviews**

Discussion and conclusions section

The strength of the evidence should be categorised using the hierarchy of evidence scale detailed in CRD report 4, available from the editorial base.

The applicability of the results should be commented on taking into account the applicability of the trials to use of the intervention in standard practice for treatment of the disorder. Cost benefit analysis will not be routinely performed.

The use of non-RCT derived data when discussing results and drawing conclusions should be commented on in this section. Where applicable, other reviews will be cross-referenced in this section.

Tables and figures

Information in the excluded and included trials tables should be brief and structured to include the Study Identifier, Methods of the Trial, Participants, Interventions, Outcomes, and further Notes.

Studies in the excluded trials table should consist of those trials which were initially selected for assessment, but which later proved to be non-RCTs or ineligible for other reasons. Advice is available from the editorial team on the validity of trials for inclusion into the review.

Table of comparisons

Policies for the structure or order of outcomes are under development and depend to some extent on the outcomes we select as 'default' for this group.

The order of trials in the tables will be alphabetical, then by date. Trials will be named preferably by author surname (e.g. Smith 1998) or, where this is not possible, by trial group identifiers (e.g. Oesophageal Cancer Trials Collaborators Group OCTCG 1997).

There may be multiple publications from one trial. Such reports should be cross referenced to the original study, for example, a publication by Jones et al reporting data from the Oesophageal Trials Collaborators Group study of 1997, should be reported as Jones 1999 (OCTCG 1997).

Any factors which could be perceived as conflict of interest should be stated.

## **Editorial process**

### **Titles**

Reviewers are invited to submit titles at any time. In order to reduce the risk of wasted effort, a title should always be registered with the Editorial Base before the reviewer starts work.

The preferred format is

[Intervention] in [disorder], and may specify in which population e.g. older people.

Newly registered titles will be publicised throughout the Cochrane Collaboration with the aim of increasing awareness of areas of potential common interest.

Protocols are normally expected within 6 months of acceptance of a title.

If more than one person proposes doing the same review then the UGPD Group will invite both persons to co-operate in the preparation of the review, either by working together, or by independently analysing data and comparing the results. The Co-ordinating Editor will work with the authors to resolve disagreements about authorship of a review.

Each review title will be assigned to a contact editor who will oversee the editorial process, supported by the editorial base in administrative matters, methodological issues and trials search and retrieval.

### **Protocols**

The UGPD Group editorial team supports reviewers in the preparation of protocols by providing methodological advice, formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials such as the handbook for reviewers and training and support as required on an ad hoc basis. Informal advice is available through the Review Group Co-ordinator.

At least three referees are asked to provide comments on each protocol. In general these will be: a person with experience of Cochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, but editors may be asked to provide referee comments for protocols other than those for which they have editorial responsibility. In the case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees.

Each review protocol will be assigned to a contact editor who will oversee the editorial process, supported by the editorial base in administrative matters, methodological issues and trials search and retrieval.

After comments from referees have been returned to the reviewer, the reviewer is asked to modify the protocol as appropriate and return this to the Review Group Co-ordinator with a commentary of the changes made and how these address the referees' comments.

Once approved by the contact editor, the editorial team will check and approve the protocol. Final approval for publication will be given by the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group.

The UGPD Group's policy for resolving disagreements between the editorial team and reviewers or between the reviewers themselves about the content of the protocol will attempt to resolve such issues by informal discussion between all those involved in production of the protocol, including the editor assigned to the protocol. In the event of an unresolvable issue, the advice of the director of the UK Cochrane Centre will be sought.

Time between submission of protocol and receipt of the completed review should normally be two years or less. After this time, protocols will be judged to have 'expired' and will be removed from the Cochrane Library with a note to that effect in the What's New section.

Referees will be sent copies of the other referees' comments and the reviewer's response, once the protocol is approved for publication.

### **Reviews**

The UGPD Group editorial team supports reviewers in the preparation of reviews by providing methodological advice, formulation and execution of search strategies, provision of RevMan software and other Cochrane Collaboration materials such as the handbook for reviewers and training and support as required on an ad hoc basis. Informal advice is available through the Review Group Co-ordinator.

At least three referees are asked to provide comments on each review, in general these will be: a person with experience of Cochrane methodology, a clinical expert and a consumer. These referees are usually from outside the editorial team, but editors may be asked to provide referee comments for reviews other than those for which they have editorial responsibility. In the case of methodological difficult or clinically contentious issues, comments may be sought from additional peer referees. Where possible comments will be sought from the same peer referees who commented on the protocol.

Each review will be assigned to a contact editor who will oversee the editorial process, supported by the editorial base in administrative matters, methodological issues and trials search and retrieval.

After comments from referees have been returned to the reviewer the reviewer is asked to modify the review as appropriate and return this to the contact editor with a commentary of the changes made and how these address the referees' comments.

Once approved by the contact editor, the editorial team will check and approve the review. Final approval for publication will be given by the Co-ordinating Editor. Copy editing will not be done routinely by the UGPD Group.

The UGPD Group's policy for resolving disagreements between the editorial team and reviewers or between the reviewers

themselves about the content of the review will attempt to resolve such issues by informal discussion between all those involved in production of the review, including the editor assigned to the review. In the event of an unresolvable issue, the advice of the director of the UK Cochrane Centre will be sought.

Referees will be sent copies of the other referees' comments and the reviewer's response, once the review is approved for publication.

### **Updating**

Reviewers will obtain newly identified information which may be relevant to their review from the specialised register on an annual basis.

Reviews will be updated whenever new studies are identified. If no new trials are found at the annual update search, a note will be made on the published review to this effect.

Updates of reviews will not normally be subject to the peer referee process as described for reviews unless the conclusions of the review are substantially altered by the addition of new data.

### **Comments and Criticisms**

Brendan Delaney is the Criticisms Editor appointed by the UGPD, and will oversee the process of dealing with comments and criticisms.

### **Out of date reviews**

Policy to be developed.

### **Disagreements about updates**

The UGPD Group's policy for resolving disagreements between the editorial team and reviewers or between the reviewers themselves about the updating of reviews will attempt to resolve such issues by informal discussion between all those involved in preparation of the review, including the editor assigned to the review. In the event of an unresolvable issue, the advice of the director of the UK Cochrane Centre will be sought.

## **Publications**

### **Publications of Cochrane UGPD Reviews**

#### **Journal Articles/Book Chapters**

Arnott S. et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data. *Int. J. Radiation Oncology Biol. Phys.*, 41 (3)579- 583. Also published as: Preoperative radiotherapy for esophageal carcinoma Tierney J. et al. *The Cochrane Library*.

Calvet X., Vergara M, Brullet E, Gisbert JP, Campo R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. *Gastroenterology* 2004; 126: 441-450.

Delaney B. et al. The management of dyspepsia: a systematic review. *Health Technology Assessment* 2000; 4(39). This publication incorporates details of several Cochrane reviews.

Delaney B. Managing dyspepsia and reflux. *The Practitioner* 2003;247:408-411

Delaney BC. et al. *Helicobacter pylori* infection. *Clinical Evidence* 2001; 5:324-337.

Delaney BC. et al. *Helicobacter pylori* infection. *Clinical Evidence* 2002; 7: 414-428. (update)

Delaney BC. et al. *Helicobacter pylori* infection. *Clinical Evidence* 2002; (update in press for issue 8)

Delaney BC, Moayyedi P. Dyspepsia. In: *Health Care Needs Assessment 3rd Series*. Edited by Stevens A, Raftery J, Mant J. Routledge, 2003(in press) also available at: <http://hcna.radcliffe-oxford.com/dysframe.htm>

Delaney BC, O'Morain C. The management of dyspepsia. *The Year in Helicobacter pylori. Current Opinion in Gastroenterology* 2001;17 (1):S38-S42.

Delaney BC. Dyspepsia and Peptic Ulcer Disease. In: *Quality indicators for General Practice*. (eds.) Marshall M, Campbell S, Hacker J, Roland M. Royal Society of Medicine; London, 2001.104-111. [Book chapter]

Delaney BC. Dyspepsia management in the millennium: to test and treat or not? *Gut* 2003; 52:10-11.

Delaney BC. *Helicobacter pylori*. *Best Treatments* 2002 (electronic media): [www.besttreatments.org](http://www.besttreatments.org)

Delaney BC. Making sense of all the dyspepsia Guidelines. *Pulse*. March 24th 2001; 60-68.

Delaney BC. Managing uninvestigated dyspepsia. *Best of DDW CD ROM. Digestive Disease Week* 2002. (electronic media



CD ROM).

Delaney BC. Modelling H. pylori 'test and treat' in Primary Care. *European Journal of General Practice* 2001;7:129-131. [Editorial]

Delaney BC. Modern diagnosis and management of dyspepsia. Member's reference book 2001. Royal College of General Practitioners; London, 2001:63-64.

Delaney BC. Test and treat for H.pylori. *Gastroimpact: Shire Health; London Autumn* 2002: 14-15.

Delaney B C and Moayyedi P. Eradicating H.pylori does not cause gastro-oesophageal reflux disease. *BMJ* 2004; 328: 1388 - 1389. [Editorial]

Dent J, Armstrong D, Delaney B, Moayyedi P, Talley N J, and Vakil N. Symptom evaluation in reflux disease Proceedings of a workshop held in Marrakech, Morocco Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. *Gut* 2004; 53 (Suppl 4): iv1-iv24.

Ford A, Delaney B. Managing Gastro-oesophageal reflux disease. Update. Nov. 2002; 4-6.

Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. *Am J Gastroenterol.* 2004; 99: 1833-55.

Fraser A, Delaney BC, Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: A systematic review. *American Journal of Gastroenterology* 2004 (in press)

Gilbert R. et al. Cisapride for GORD in infants. *Journal of Paediatrics and Child Health*, 2000; 36:524-529. Also published as Cisapride treatment for gastro-oesophageal reflux in children Augood C et al. *The Cochrane Library*.

JP Gisbert, S Khorrami, F Carballo, X Calvet, E Gene, E Dominguez-Muñoz. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. *Aliment Pharmacol Ther* 2004; 19: 617-629.

Jankowski J. et al. 10 minute consultation: Gastro-oesophageal reflux disease (GORD). *BMJ* 2002;325:945

Katzka D. et al. Gastro-oesophageal reflux disease. *Clinical Evidence* 2000; Issue 4:253-265.

Logan RFA, Delaney BC. Implications of dyspepsia for the NHS. In: *ABC of the Upper Gastrointestinal tract.* (eds) Logan RPH, Harris A, Misiewicz JJ, Baron JH. *BMJ Books; London*, 2002. ISBN 0-7279-1266-6.

Moayyedi P. et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. *BMJ* 2000, 321:659-664. Also published as Eradication of Helicobacter pylori for non-ulcer dyspepsia Moayyedi P et al. *The Cochrane Library*.

Moayyedi P. et al. Helicobacter pylori eradication therapy for nonulcer dyspepsia. *Annals of Internal Medicine* 2002; 136: 555-6.

Moayyedi P. et al. Systematic review: antacids, H2 receptor antagonists, prokinetics, bismuth and sucralfate therapy for non ulcer dyspepsia. *Alimentary Pharm and Ther* 2003;17:1215-1227.

Moayyedi P. et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2003; 17: 1207-14.

Moayyedi P, Delaney B, Forman D. Gastro-oesophageal reflux disease. *Clinical Evidence* 2003; 9: 89-91.

Moayyedi P. Helicobacter pylori eradication in non-ulcer dyspepsia: the case for. In: *Helicobacter pylori: Basic mechanisms to clinical cure* 2002. Eds. Hunt RH, Tytgat GNJ. *Kluwer Academic Publishers, Dordrecht* 2002; 265-274.

Moayyedi P, Delaney BC, Katzka D, Forman D. Gastro-oesophageal reflux disease. *Clinical Evidence* 2000; issue 4: 253-265

Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. *Am J Gastroenterol* 2003; 98: 2621-6.

Moayyedi P, Soo S, Deeks J, Forman D, Harris A, Innes M, Delaney B. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. *Alimentary Pharmacology and Therapeutics* 2003; 17: 1207-14.

Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ, The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. *Gastroenterology* 2004; 127:1329-37.

Moayyedi P, Duffy J, Delaney B. Symptom evaluation in reflux disease Proceedings of a workshop held in Marrakech, Morocco New approaches to enhance the accuracy of the diagnosis of reflux disease. *Gut* 2004; 53 (Suppl 4): iv55-iv57.

Rostom A. et al. Canadian co-ordination office for health technology assessment. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Due for publication in September 2003

Rostom A. et al. Prevention of NSAID-induced upper GI toxicity. (manuscript submitted to *Rheumatology*) Also published as Prevention of NSAID-induced gastroduodenal ulcers Rostom A et al. *The Cochrane Library*.

Rostom, G. et al. The prevention of NSAID Induced Upper Gastrointestinal Toxicity: A meta-Analysis of Randomized controlled Trials. *J of Rheum sept.* 2000; 27(9):2203-14.

Sharma N, Donnellan C, Preston C, Delaney B, Duckett G, Moayyedi P. Symptom evaluation in reflux disease Proceedings of a workshop held in Marrakech, Morocco A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. *Gut* 2004; 53 (Suppl 4): iv58-iv65.

Soo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. *Am J Gastroenterol.* 2004; 99: 1817-22.

Soo S. et al. A systematic review of pharmacological therapies in non-ulcer dyspepsia. *Gut* 2000; 46: (suppl 11): A88

Soo S. A systematic review of pharmacological therapies in non-ulcer dyspepsia. *Digestive Disease Week, San Diego, USA 2000 (Gastroenterology 2000; 118: A440)*

Talley NJ, Marshall BJ, Bytzer P, Engstrand L, de Boer W, Vakil N, Delaney B, Jones R, Malfertheiner P, Agréus L. Management Issues in Dyspepsia: Current Consensus and Controversies. *Scandinavian Journal of Gastroenterology* (in press)

Van Binsbergen JJ. et al. Nutrition in Primary Care: scope and relevance of output from the Cochrane Collaboration. *American Journal of Clinical Nutrition.* 2003;77: 1083-1088.

Van Pinxteren B. et al. GERD in primary care. (manuscript in preparation). Also published as Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease van Pinxteren B et al. *The Cochrane Library*.

van Pinxteren B. et al. Short-term Treatment of Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of the Effect of Acid Suppressant Drugs. *J Gen Int Med* 2003, accepted

van Pinxteren B. et al. (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. *Health Technology Assessment Monographs* 5:(24).

#### Abstracts/Oral/Poster Presentations

Delaney B. et al. Effectiveness of prompt endoscopy in the management of dyspepsia: a systematic review. *Digestive Disease Week, Atlanta USA, 20-23 May 2001.*

Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. 3rd. Symposium on systematic reviews, Oxford July 4-6 2000.

Delaney B. on behalf of the Dyspepsia Review Group. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. *European Society for Medical Decision Making ASM. Leiden, Netherlands June 16th. 2000.*

Delaney B. Increasing the impact of meta-analyses on decision-makers: adding cost information to a systematic review of the effectiveness of *Helicobacter pylori* eradication for non-ulcer dyspepsia. 9th Cochrane Colloquium, Cape Town, South Africa. October 21-29th 2000.

Delaney B. et al. Cost-Effectiveness of Early Endoscopy for Dyspepsia in Patients of 50 Years of Age and Over: Results of a Primary Care Based Randomised Controlled Trial. *Digestive Disease Week, San Diego USA, 20-24 May 2000.*

Delaney BC, Moayyedi P. Cost-effectiveness of maintenance therapies for oesophagitis: a 2nd order monte carlo simulation based on a meta-analysis. *Society for Medical Decision Making. Chicago, Illinois, USA. October 18-22nd 2003. (Oral)*

Delaney BC, Barton PM, Moayyedi P, Wilson S. A Discrete Event Simulation Of The Cost-Effectiveness Of Detecting Upper Gi Cancer By Prompt Endoscopy In Dyspeptic Patients Above Different Ages. *Society for Medical Decision Making. Chicago, Illinois, USA. October 18-22nd 2003. (Poster)*

Delaney BC, Qume M, Ford A, O'Rourke K, Moayyedi P, The management of dyspepsia in primary care: a prospective individual patient data meta-analysis of health economic RCTs. Cochrane Colloquium, Barcelona, Spain 25th-31st October 2003. (poster)

Delaney BC, Moayyedi P, Mason M. Using Cochrane Reviews And Modelling In The Development Of UK National Guidelines On Dyspepsia. Cochrane Colloquium, Barcelona, Spain 25th-31st October 2003. (Oral)

Delaney BC, Qume M, Ford A, Moayyedi P, on behalf of the Dyspepsia Trials Collaborators' Group. The management of dyspepsia in primary care: a prospective individual patient data meta-analysis of health economic RCTs. European Society For Medical Decision Making, Rotterdam June 2004 (Poster)

Delaney BC, Moayyedi P, Mason M. Using Cochrane Reviews And Modelling In The Development Of UK National Guidelines On Dyspepsia. European Society For Medical Decision Making, Rotterdam June 2004 (Poster)

Delaney BC, Ford A, Qume M, Moayyedi P, . Test and treat v. prompt endoscopy: an individual patient data meta-analysis. North American Primary Care Research Group, Orlando, USA 12th Oct 2004. (Oral)

Delaney BC, Ford A, Qume M, Moayyedi P. Test and treat v. prompt endoscopy: an individual patient data meta-analysis. Society for Medical Decision Making, Atlanta, USA 19th Oct 2004. (Poster)

Ford A, Qume M, Moayyedi P, Delaney BC. Test and treat v. prompt endoscopy: an individual patient data meta-analysis. Digestive Disease Week New Orleans, USA 19th May 2004. (Oral)

Gisbert, J. H. pylori (HP) Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding (RB) from Peptic Ulcer (PU): a Cochrane Systematic (Helicobacter 2004; 9: 567)

Gisbert J.P., Khorrami S., Carballo F., Calvet X., Gene E., Dominguez-Muñoz E., Pajares J.M., H. pylori (HP) Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding (RB) from Peptic Ulcer (PU): a Cochrane Systematic Review.. Gastroenterology 2004; 126 (Suppl.2): T1185. Presented in the last European Helicobacter Study Group Congress in Vienna has been awarded as "Poster of Distinction".

Innes M.A. et al. Managing dyspepsia in primary care: a systematic review. Association of University Departments of General Practice, Annual Scientific Meeting, London 1999.

Innes M.A. et al, Managing dyspepsia in Primary Care: A systematic review. Gastroenterology 2000; 118 Suppl 2: A1249.

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Cochrane collaboration systematic review and meta-analysis of proton pump inhibitor treatment for peptic ulcer bleeding. Gut 2003; 52 (Suppl IV): A18 11th United European Gastroenterology Week, Madrid, 1-5 November 2003.

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Influence of geographical location of randomized controlled trials on effectiveness of PPI treatment in ulcer bleeding: A post hoc analysis of a Cochrane Collaboration systematic review. Gastroenterology 2004, 126: A-192 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Efficacy of PPI treatment for ulcer bleeding when compared with placebo or an H2-receptor antagonist: A sub-group analysis from the Cochrane Collaboration systematic review. Gastroenterology 2004; 126: A-193 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. Does the efficacy of PPI treatment for ulcer bleeding depend on the nature of pre-randomization endoscopic stigmata? A post hoc analysis from the Cochrane Collaboration systematic review. Gastroenterology 2004; 126: A-603 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Leontiadis G I, McIntyre L, Sharma V K, Howden C W. The influence of PPI dose on treatment efficacy for ulcer bleeding following endoscopic emostatic therapy: A sub-group analysis from the Cochrane Collaboration systematic review. Gastroenterology 2004; 126: A-602 105th Annual meeting of the American Gastroenterological Association, Digestive Diseases Week, New Orleans, LA, May 2004

Moayyedi P. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD) British Society of Gastroenterology, Birmingham, UK 2000 (Gut 2000; 46 (suppl 11): A51

Moayyedi P. et al. A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD). Gastroenterology 2000; 118: A471

Moayyedi P. et al. Markov modelling with probabilistic sensitivity analysis based on meta-analysis: cost-effectiveness of Helicobacter pylori eradication for non-ulcer dyspepsia. Society for Medical Decision Making, 22nd Annual Scientific Meeting, Cincinnati, USA. September 24-27th 2000. (Poster presentation)

van Pinxteren B. et al. Short-term Treatment with Proton Pump inhibitors, H<sub>2</sub>-receptor antagonists and Prokinetics in Gastroesophageal Reflux Disease: A systematic review. Poster Presentation at DDW 2000, San Diego CA, USA, May 22 2000 (abstract published in Gastroenterology).

Wong, K.S.R. Is combination radiotherapy chemotherapy (RTCT) superior to radiotherapy (RT) alone in the non-surgical management of localized esophageal carcinoma? A systematic review. (abstr) Suppl Clin Inv Med 372 S50 1999. Royal College of Physicians and Surgeons of Canada. Montreal, Quebec. September 1999.

Wong K.S.R. Meta-analysis of Combined Chemotherapy and Radiotherapy for Esophageal Cancer. ASTRO, American Society of Therapeutic Radiation Oncology. San Antonio, TX. September 1999.

#### Plenaries and Workshops

Briggs A, Delaney BC; Schulpher M, Claxton K. Stochastic cost-effectiveness modelling. Society for Medical Decision Making. Chicago, Illinois, USA. October 21st 2003. (invited postgraduate course)

Delaney B.C. The role of quality of life measurement in the clinical assessment of GERD. Symptom assessment in reflux disease. Marrakech, Morocco, 7-8th September 2002.

Delaney B.C. Test and treat strategies for H.pylori in the management of dyspepsia. Chris Silagy memorial lecture: The impact of systematic reviews on primary care. Kellog College, Oxford. 26th Sept 2002.

Delaney B.C. 'Pragmatic' RCTs : planning, conduct and analysis of RCTs with cost-effectiveness as the primary outcome. Epidemiology Grand Round, McGill University Health Centre, Montreal Canada, October 8th 2002.

Delaney B.C. A Bayesian approach to dyspepsia: working with uncertainty at the interface between research and practice. Invited lecture, Montreal, Canada 8th October 2002.

Delaney B.C. The Cochrane Collaboration and the evidence-base for managing dyspepsia. Gastroenterology Grand Round, Montreal General Hospital, Montreal, Canada. 9th October 2002.

Delaney B. Effectiveness of empirical treatments for undiagnosed dyspepsia. Primary Care Society for Gastroenterology Symposium at The British Society of Gastroenterology ASM, Birmingham, March 21-23, 2000.

Delaney B. Evidence-based management of dyspepsia. Primary Care Society for Gastroenterology ASM, Birmingham, October 13th 2000.

Delaney B. Vale L. Exploring uncertainty in economic analysis: ways of extending systematic reviews to address issues of cost-effectiveness. 9th Cochrane Colloquium, Cape Town, South Africa. October 21-29th 2000. (Invited Workshop)

Delaney BC. Managing dyspepsia in primary care. XVIth International Workshop Gastrointestinal Pathology and Helicobacter. Stockholm 4-6 September 2003.

Delaney BC. Prevalence and epidemiology of GERD. Europe-Japan Joint Expert meeting, London, 22nd Sept 2003.

Delaney BC. Managing dyspepsia in Primary Care A new Cochrane individual patient data meta-analysis. (AGA Special Symposium) Digestive Disease week, New Orleans, USA 19th May 2004.

Delaney BC. Management of Dyspepsia. (invited talk) WONCA-Europe, Amsterdam 3 June 2004.

Delaney BC. Dyspepsia management: H pylori and beyond (invited talk). United European Gastroenterology week, Prague 27th Sept 2004.

Delaney BC. Approach to the patient with dyspepsia (lunch session). United European Gastroenterology week, Prague 28th Sept 2004.

Delaney BC. Dyspepsia: Test and treat. Takeda Satellite symposium: United European Gastroenterology week, Prague 28th Sept 2004

Delaney BC. Acute management of the patient with Gastroesophageal reflux disease: Workshop on Gastrointestinal Disease, Paris 21st Oct 2004

Incorporation of reviews into guidelines/discussion of reviews at meetings (e.g. consensus conferences)

NHS Executive Evidence Review: "Improving Outcomes in Upper GI Cancers". This evidence review has been published and used by the NHS Centre for Research and Development in the development of their manual: "Guidance on Commissioning Cancer Services: Upper GI Cancer". The Manual will, in turn, be used by Health Authorities to provide guidance in the commissioning of relevant services.

The review "Short-term treatment with proton pump inhibitors, H<sub>2</sub>-receptor antagonists and prokinetics for gastro-oesophageal

reflux disease-like symptoms and endoscopy negative reflux disease" will be included in primary care guidelines by the European Society for Primary Care Gastroenterology.

The HTA Report: "Managing the Dyspeptic Patient" will be used as the evidence base for the production of guidelines by the British Society of Gastroenterology.

Dr R. Malthaner (UGPD editor and reviewer) and Dr Wong (UGPD reviewer) are contributing reviews of chemo- or radiotherapy as adjuvant or neoadjuvant therapy for oesophageal resectable cancer and took the lead in drafting and revising the Cancer Care Ontario Practice Guidelines Initiative, recently submitted to "Cancer Practice and Control".

Tierney, J The results of the pre-op RT in oesophageal cancer are included in the British Columbia Cancer Agency Cancer Management Guidelines for Gastrointestinal Cancer.  
<http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gastrointestinal/01.EsophagusAndCardia/Management/Localiz>

## References

## Additional information